The earnings call showcased several positive developments including the completion of dosing in a key trial, strong financial standing, strategic collaborations, and promising long-term data. However, concerns over suicidality and challenges related to trial variability and placebo effects were noted, which are significant but not overwhelming.

Company Guidance -

Q1 2025

During the COMPASS Pathways First Quarter 2025 Earnings Call, key guidance was provided regarding their pivotal Phase III trials for COMP360 in treatment-resistant depression (TRD). The company announced the completion of dosing in Part A of their 005 trial, with top-line results expected in late June, focusing on the difference in change from baseline on the MADRS scale, associated p-value, and confidence interval. Enrollment for the second Phase III trial, COMP006, is progressing well, targeting 26-week results in the second half of 2026. The call also highlighted successful financial positioning, with cash and equivalents at $260 million, sufficient to fund operations through the COMP006 readout. Additionally, strategic collaborations, including a new partnership with HealthPort, aim to enhance access to innovative mental health treatments, potentially including COMP360, if FDA approved.

Completion of Dosing in Phase 3 Trial

COMPASS Pathways announced the completion of dosing for all participants in Part A of their pivotal Phase III trial for treating resistant depression (TRD), marking an important milestone.

Strong Financial Position

The company reported cash and cash equivalents of $260 million at the end of March, up from $165 million at the end of 2024, expected to fund operations through Phase 3 trial COMP006 data readout in 2026.

Strategic Collaboration with HealthPort

COMPASS Pathways announced a strategic collaboration with HealthPort, a community health center focused on equitable access to mental health treatments, highlighting the company’s focus on underserved populations.

Positive Long-term Data from Phase 2b Trial

52-week follow-up data from the Phase 2b trial showed that a single 25 mg dose of COMP360 offered long-term benefits, with an average time to depressive event of over 12 weeks.

COMPASS Pathways (CMPS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CMPS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 31, 2025	2025 (Q2)	-0.43 / -	-0.56	―	―	―
May 08, 2025	2025 (Q1)	-0.47 / -0.24	-0.55	56.36% (+0.31)	―
Feb 27, 2025	2024 (Q4)	-0.63 / -0.63	-0.53	-18.87% (-0.10)	―
Oct 31, 2024	2024 (Q3)	-0.57 / -0.56	-0.67	16.42% (+0.11)	―
Aug 01, 2024	2024 (Q2)	-0.54 / -0.56	-0.62	9.68% (+0.06)	―
May 08, 2024	2024 (Q1)	-0.48 / -0.55	-0.57	3.51% (+0.02)	―
Feb 29, 2024	2023 (Q4)	-0.36 / -0.53	-0.73	27.40% (+0.20)	―
Nov 02, 2023	2023 (Q3)	-0.52 / -0.67	-0.43	-55.81% (-0.24)	―
Aug 03, 2023	2023 (Q2)	-0.71 / -0.62	-0.5	-24.00% (-0.12)	―
May 11, 2023	2023 (Q1)	-0.69 / -0.57	-0.5	-14.00% (-0.07)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CMPS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 08, 2025	$3.74	$3.76	+0.53%
Feb 27, 2025	$3.70	$3.92	+5.95%
Oct 31, 2024	$6.19	$4.76	-23.10%
Aug 01, 2024	$7.63	$6.88	-9.83%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Compass Pathways Plc (CMPS) report earnings?

Compass Pathways Plc (CMPS) is schdueled to report earning on Jul 31, 2025, Before Open (Confirmed).

What is Compass Pathways Plc (CMPS) earnings time?

Compass Pathways Plc (CMPS) earnings time is at Jul 31, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CMPS EPS forecast?

CMPS EPS forecast for the fiscal quarter 2025 (Q2) is -0.43.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing